TCG Crossover Management
Latest statistics and disclosures from TCG Crossover Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, DYN, ABVX, SLN, COGT, and represent 42.81% of TCG Crossover Management's stock portfolio.
- Added to shares of these 8 stocks: ABVX (+$66M), IRON (+$22M), SVRA (+$9.5M), EYPT (+$8.0M), CNTA (+$7.7M), COGT (+$6.3M), CGON, AVTE.
- Started 2 new stock positions in EYPT, IRON.
- Reduced shares in these 7 stocks: Inhibrx (-$61M), GERN (-$57M), GPCR (-$36M), ATXS (-$23M), KALV (-$14M), TARS (-$6.5M), VTYX.
- Sold out of its positions in GERN, Inhibrx, KALV.
- TCG Crossover Management was a net seller of stock by $-76M.
- TCG Crossover Management has $960M in assets under management (AUM), dropping by -24.14%.
- Central Index Key (CIK): 0001839948
Tip: Access up to 7 years of quarterly data
Positions held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 32 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology Comm (CGON) | 12.1 | $116M | +2% | 3.7M | 31.57 |
|
| Dyne Therapeutics Comm (DYN) | 9.7 | $94M | 2.7M | 35.29 |
|
|
| Abivax SA Adrs (ABVX) | 8.3 | $80M | +450% | 6.1M | 13.22 |
|
| Silence Therapeutics Adrs (SLN) | 6.5 | $63M | 3.3M | 19.00 |
|
|
| Cogent Biosciences Comm (COGT) | 6.1 | $59M | +12% | 7.0M | 8.43 |
|
| Savara Comm (SVRA) | 5.2 | $50M | +23% | 12M | 4.03 |
|
| Madrigal Pharmaceuticals Comm (MDGL) | 4.4 | $42M | 149k | 280.16 |
|
|
| Edgewise Therapeutics Comm (EWTX) | 4.3 | $41M | 2.3M | 18.01 |
|
|
| Keros Therapeutics Comm (KROS) | 4.2 | $40M | 879k | 45.70 |
|
|
| Mineralys Therapeutics Comm (MLYS) | 3.9 | $37M | 3.2M | 11.70 |
|
|
| Ocular Therapeutix Comm (OCUL) | 3.8 | $36M | 5.3M | 6.84 |
|
|
| Tyra Biosciences Comm (TYRA) | 3.3 | $32M | 2.0M | 15.99 |
|
|
| Kura Oncology Comm (KURA) | 3.1 | $29M | 1.4M | 20.59 |
|
|
| Structure Therapeutics Adrs (GPCR) | 2.8 | $27M | -56% | 695k | 39.27 |
|
| Centessa Pharmaceuticals Comm (CNTA) | 2.7 | $26M | +41% | 2.9M | 9.03 |
|
| Astria Therapeutics Comm (ATXS) | 2.6 | $25M | -47% | 2.8M | 9.10 |
|
| Compass Pathways Adrs (CMPS) | 2.4 | $23M | 3.9M | 6.04 |
|
|
| Soleno Therapeutivs Comm | 2.3 | $22M | 550k | 40.80 |
|
|
| Disc Medicine Comm (IRON) | 2.3 | $22M | NEW | 487k | 45.07 |
|
| Tourmaline Bio Comm (TRML) | 2.0 | $19M | 1.5M | 12.86 |
|
|
| Tarsus Pharmaceuticals Comm (TARS) | 1.6 | $15M | -29% | 556k | 27.18 |
|
| Adverum Biotechnologies Comm | 1.4 | $14M | 2.0M | 6.86 |
|
|
| Vistagen Therapeutics Comm | 1.0 | $9.3M | 2.7M | 3.48 |
|
|
| Entrada Therapeutics Comm (TRDA) | 0.9 | $8.3M | 585k | 14.25 |
|
|
| EyePoint Pharmaceuticals Comm (EYPT) | 0.8 | $8.0M | NEW | 922k | 8.70 |
|
| C4 Therapeutics Comm (CCCC) | 0.6 | $5.9M | 1.3M | 4.62 |
|
|
| Nektar Therapeutics Comm (NKTR) | 0.5 | $5.0M | 4.0M | 1.24 |
|
|
| Aerovate Therapeutics Comm (AVTE) | 0.4 | $3.7M | 2.2M | 1.66 |
|
|
| AN2 Therapeutics Comm (ANTX) | 0.3 | $3.3M | 1.6M | 2.15 |
|
|
| Kodiak Sciences Comm (KOD) | 0.2 | $2.1M | 900k | 2.35 |
|
|
| Ventyx Biosciences Comm (VTYX) | 0.1 | $730k | -61% | 316k | 2.31 |
|
| Cabaletta Bio Comm (CABA) | 0.1 | $649k | 87k | 7.48 |
|
Past Filings by TCG Crossover Management
SEC 13F filings are viewable for TCG Crossover Management going back to 2021
- TCG Crossover Management 2024 Q2 filed Aug. 14, 2024
- TCG Crossover Management 2024 Q1 filed May 15, 2024
- TCG Crossover Management 2023 Q4 filed Feb. 14, 2024
- TCG Crossover Management 2023 Q3 filed Nov. 14, 2023
- TCG Crossover Management 2023 Q2 filed Aug. 14, 2023
- TCG Crossover Management 2023 Q1 filed May 15, 2023
- TCG Crossover Management 2022 Q4 filed Feb. 14, 2023
- TCG Crossover Management 2022 Q3 filed Nov. 14, 2022
- TCG Crossover Management 2022 Q2 filed Aug. 15, 2022
- TCG Crossover Management 2022 Q1 filed May 16, 2022
- TCG Crossover Management 2021 Q4 filed Feb. 18, 2022